Rhia Ventures

Twentyeight Health is building a digital healthcare home for underserved women, providing telemedicine, medication delivery, and care coordination. Twentyeight Health is revolutionizing access to high-quality, inclusive women's health services for Medicaid recipients.

YourChoice Therapeutics develops a non-hormonal contraceptive product. Its technology is based on the “molecular condom” concept: the active compound inhibits vigorous sperm motility and prevents sperm from fertilizing the egg.

Cayaba Care is a maternal health company that provides virtual and in-person wrap-around support throughout the pregnancy and postpartum journey for medium and high risk women. Our multidisciplinary approach is anchored by Maternity Navigators–also certified doulas–who partner with members to ensure successful birth outcomes. We support commercial and Medicaid plans through standard and value-based care contracts to improve quality, experience and achieve significant cost-savings.

The mission of the Fogarty Institute for Innovation is to promote medical innovation by providing support to promising innovators and researchers as they transform their creative ideas into practical solutions to improve patient care. They offer mentorship and education at every step of the process, coordinating access to intellectual, physical, and financial resources to propel medical concepts from initiation to application.

Raydiant Oximetry is a medical device company focused on improving outcomes for mothers and babies during childbirth. The company develops a low-cost, non-invasive biomedical device to monitor the oxygen levels in fetal blood. It develops and distributes a non-invasive technology that directly monitors a babies' oxygenation during pregnancy. This technology will lead to better patient care and greatly reduce the number of unnecessary cesarean sections. Founded in 2015 by Neil Ray, Raydiant Oximetry is headquartered in Mountain View, California.

Testmate Health is a medtech startup and award-winning spin-off of University of Geneva (Switzerland). We have developed a smartphone compatible platform test kit that diagnoses any disease with an identifiable DNA or RNA sequence - without the need for a lab, providing results directly at home in minutes. Based on this platform, our first solution is the first rapid urine self-test for the four most common sexually transmitted diseases (STD). One million new STDs are diagnosed a day, and yet the best improvements to date still need a lab, with results taking up to 7 days to be ready. Our easy to use all-in-one-kit provides results in minutes, anywhere, at any time, and the result is scannable by a smartphone to enable people to immediately gain access to treatment – if needed. Further test-kits with other diseases are in the pipeline to empower users to skip the waiting room, and take charge of their health from home.

Contraline is developing the first long-lasting, non-hormonal, reversible contraceptive for men

Mae is a women's health care center providing pregnancy and postpartum support, tailored to women's needs. Mae is establishing a world in which high-quality, proactive care is the norm. Mae improves the quality of care for Black women by providing a trusted, digital-first health platform.

OCON Healthcare innovates, develops, manufactures, and commercializes cutting-edge women’s health products based on our patented IUB™ (Intra Uterine Ball) proprietary platform. The IUB™, made from a super-elastic alloy Nitinol, is an ideal carrier for multiple drugs to the uterus to treat a variety of conditions. In addition to our flagship product, the IUB™ Ballerine®, OCON healthcare is developing an innovative pipeline of products utilizing the IUB™ frame for indications such as abnormal uterine bleeding (AUB), heavy menstrual bleeding (HMS), myomas/fibroids, and infertility.

Cirqle Biomedical focuses on creating a novel contraceptive method that enhances the natural cervical mucus barrier to prevent sperm penetration. The company's approach aims to provide effective birth control without hormones, addressing the needs of women seeking alternatives to traditional contraceptive methods. Currently in pre-clinical development, this technology represents a significant advancement in women's reproductive health.